ClinConnect ClinConnect Logo
Search / Trial NCT06873204

Impact of Soluble Arabinoxylan and Rice Bran Fiber on the Gut Microbiome in Healthy Adults

Launched by PURDUE UNIVERSITY · Mar 6, 2025

Trial Information

Current as of May 09, 2025

Not yet recruiting

Keywords

Gut Microbiota Dietary Fiber Soluble Arabinoxylan Rice Bran Fiber Intestinal Health Butyrate Producing Bacteria Clostridium Cluster I Va Short Chain Fatty Acids

ClinConnect Summary

This clinical trial is studying how two types of fiber supplements—soluble arabinoxylan and stabilized rice bran—affect gut health in healthy adults. Researchers want to find out if these fibers can improve the gut microbiome, which is the community of bacteria in our intestines that plays a crucial role in our overall health. Participants will take either of the two fiber supplements or a placebo (a harmless substance with no active ingredients) for three weeks each, with a break in between. They will also provide blood and stool samples and keep a diary of their food intake and any gastrointestinal symptoms during the study.

To be eligible for this trial, participants need to be healthy men or women between the ages of 18 and 45, with a normal body weight (a body mass index between 18.5 and 25). It’s important that they can read and speak English. However, individuals with certain gastrointestinal disorders, those who have recently taken antibiotics, or anyone on medications or diets that might affect their gut health are not eligible. This study is not yet recruiting participants, so if you or someone you know meets the criteria and is interested, it may be worth keeping an eye out for when recruitment begins.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Men or women.
  • Aged between 18-45 years.
  • Body mass index between 18.5 and 25 kg/m².
  • Able to read/speak English.
  • Exclusion Criteria:
  • Gastrointestinal disorders (inflammatory bowel disease, irritable bowel syndrome, gluten sensitivity/intolerance, etc.).
  • Those who took antibiotics 3 months before the study.
  • Individuals taking regular medication or supplements that might affect the gut microbiota.
  • Individuals undertaking weight-loss diets.
  • Unstable body weight (±3 kg in the past 3 months), and individuals below 110 lb.
  • Heavy drinkers (for men, consuming more than 4 drinks on any day or more than 14 drinks per week; for women, consuming more than 3 drinks on any day or more than 7 drinks per week).
  • Smokers (those who have smoked 100 cigarettes in their lifetime and who currently smoke cigarettes, even every day or occasionally).
  • Breastfeeding or pregnant women.

About Purdue University

Purdue University is a renowned research institution dedicated to advancing knowledge and innovation across various fields, including health and medicine. As a clinical trial sponsor, Purdue leverages its extensive academic resources and multidisciplinary expertise to conduct rigorous research aimed at improving patient outcomes and contributing to the scientific community. With a commitment to ethical standards and regulatory compliance, Purdue University collaborates with healthcare professionals and industry partners to translate research findings into practical applications, ultimately enhancing the quality of care and addressing critical health challenges.

Locations

West Lafayette, Indiana, United States

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported